Last chance therapies and managed care - Pluralism, fair procedures, and legitimacy

被引：49

作者：

Daniels, N ^{[1
]}

Sabin, JE

机构：

[1] Tufts Univ, Medford, MA 02155 USA

[2] Harvard Pilgrim Hlth Ctr, Ctr Eth Managed Care, Cambridge, MA USA

来源：

HASTINGS CENTER REPORT | 1998年 / 28卷 / 02期

关键词：

D O I：

10.2307/3527569

中图分类号：

B82 [伦理学（道德学）];

学科分类号：

摘要：

How can health plans make fair determinations about when "experimental" (and costly) treatments such as high dose chemotherapy with autologous bone marrow transplantation should be covered despite lack of clear clinical consensus about their benefits? Different models for managing "last chance" therapies evolving in some health plans offer promising examples of how issues of fairness and legitimacy in decisionmaking can be addressed.

引用

页码：27 / 41

页数：15

共 23 条

[1]

Beebe D B, 1997, HMO Pract, V11, P65

[2]

Benhabib Seyla., 1996, DEMOCRACY DIFFERENCE, P95

[3] RETRACTED: HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY-TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL (Retracted article. See vol. 19, pg. 2973, 2001) [J].